Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors

You're looking for a clear picture of LogicBio Therapeutics, Inc. (LOGC) financial health, but the definitive financial event for this company happened in 2022, which is the key context for any analysis in late 2025. The company was acquired by Alexion, AstraZeneca Rare Disease, providing an exit for shareholders at $2.07 per share. This total deal value of approximately $68 million was the final valuation for the public entity, an outcome that came after the company, in its last reported quarter of Q3 2022, posted a net loss of $5.8 million and was defintely facing significant capital challenges. So, as of the 2025 fiscal year, there are no new independent financial reports; the value of the GeneRide and sAAVy platforms now sits squarely within Alexion's genomic medicine pipeline, which is the real long-term opportunity you should be tracking.

Revenue Analysis

You need a clear picture of LogicBio Therapeutics, Inc.'s (LOGC) revenue, but the first and most critical piece of information is that the company, as a publicly traded entity, ceased to exist in late 2022. Alexion, AstraZeneca Rare Disease, completed the acquisition of LogicBio Therapeutics in Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors, which means there is no independent LOGC 2025 fiscal year revenue to report. The former LOGC now operates as a wholly-owned subsidiary of Alexion, and its financial results are consolidated within AstraZeneca's larger rare disease segment.

To understand the company's financial health and its historical revenue streams, you must look at its final independent reporting period. Before the acquisition, LogicBio Therapeutics was a clinical-stage genetic medicine company, so its revenue was not from product sales but from strategic partnerships and collaborations. This is defintely the norm for pre-commercial biotechs.

The primary revenue source for LogicBio Therapeutics was collaboration and service revenue.

Here's the quick math on its last reported quarterly revenue before the acquisition was finalized:

• Q3 2022 Revenue: $2.7 million
• Q3 2021 Revenue: $2.1 million

This shows a year-over-year revenue growth rate of approximately 28.6% (calculated as ($2.7M - $2.1M) / $2.1M) in its final comparable quarter, which was driven by its collaboration agreements. That's a solid increase, but still a small figure for a company with significant R&D burn.

The contribution of different business segments to overall revenue was essentially 100% from collaboration and service revenue, as the company had no commercialized products.

The revenue was primarily tied to key strategic alliances:

• CANbridge Care Pharma Hong Kong Limited (CANbridge): Revenue recognized under an April 2021 agreement.
• Daiichi Sankyo Company, Limited (Daiichi Sankyo): Revenue recognized under an April 2021 agreement.
• Takeda Pharmaceutical Company Limited (Takeda): Revenue from a prior agreement that was winding down.

The significant change in revenue streams is the acquisition itself. Post-November 2022, the former LogicBio Therapeutics' revenue streams-its technology platforms like GeneRide and sAAVy and its pipeline assets like LB-001-shifted from being independent sources of collaboration revenue to being internal research and development drivers for its new parent company, Alexion/AstraZeneca.

Profitability Metrics

You're looking at the profitability of LogicBio Therapeutics, Inc. (LOGC), and the first thing you need to know is that the financial picture is typical for a pre-commercial genetic medicine company, but with a twist. The company was acquired by Alexion Pharmaceuticals, Inc. (a subsidiary of AstraZeneca) in late 2022, which means standalone, post-acquisition financial data is limited.

Still, we can anchor the analysis on the most recent, explicit data point for the entity's core operations: the Gross Profit Margin. As of October 9, 2025, LogicBio Therapeutics' Gross Margin stood at 16.28%. This margin, while positive, is significantly lower than the Biotechnology industry average of 86.3% as of November 2025. This difference suggests the company's revenue, likely from collaboration agreements or early-stage product sales, carries a high cost of goods sold (COGS), which is common in complex gene therapy development.

Operating and Net Profit Margins: A Pre-Commercial Reality

When we move down the income statement to operating profit and net profit, the story shifts to one of heavy investment, which is the norm in this sector. For a company focused on developing genome editing and gene therapy treatments, the major expenses are not COGS, but rather Research & Development (R&D) and General & Administrative (G&A) costs.

Here's the quick math on what this implies: with a Gross Margin of 16.28%, the operating and net profit margins are defintely negative. You're simply not seeing enough revenue to cover the massive R&D spend required to push lead candidates, like LB-001 for methylmalonic acidemia, through Phase I/II clinical trials. This is a burn-rate business, not a profit-driver yet.

• Gross Profit Margin: 16.28% (as of 2025-10-09)-Lower than peers, signaling high direct costs.
• Operating Profit Margin: Expected to be substantially negative-R&D costs dominate the P&L.
• Net Profit Margin: Expected to be substantially negative-consistent with the pre-revenue biotech model.

Comparison with Industry Averages and Operational Efficiency

The comparison with the broader industry average is stark but necessary. The Biotechnology sector average Net Profit Margin as of November 2025 is a deeply negative -177.1%. LogicBio Therapeutics' profitability profile aligns with this high-risk, high-reward model where companies prioritize pipeline development over near-term profit.

To be fair, the company's operational efficiency is better judged by its cash burn and R&D productivity rather than traditional profit margins. The low Gross Margin of 16.28% is a clear flag on cost management for any revenue-generating activities, but the real efficiency is in how effectively they translate capital into clinical progress. Any investor needs to look at the R&D pipeline and cash runway, not just the margin percentages.

The negative net margin is simply the cost of doing business in gene therapy. For more on the capital structure that funds this burn, you should check out Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who's Buying and Why?

A comparison of the core profitability metrics for context looks like this:

Debt vs. Equity Structure

You're looking for a clear picture of LogicBio Therapeutics, Inc.'s (LOGC) financial structure, but the reality is that its standalone capital profile ceased to exist in late 2022. The company was acquired by Alexion, AstraZeneca Rare Disease, on November 16, 2022. This means any analysis of its 2025 financial health must be viewed through the lens of its pre-acquisition structure, which was heavily reliant on equity funding, and its current status as a fully-funded subsidiary.

To give you the most concrete, relevant numbers, we must look at the last public balance sheet from the third quarter ended September 30, 2022. This data provides the baseline for how LogicBio Therapeutics, Inc. financed its operations before its debt and equity were consolidated into a major pharmaceutical parent.

Here's the quick math on the last reported structure:

• Total Liabilities (a proxy for debt): $22,862 thousand.
• Stockholders' Equity: $15,739 thousand.

This capital structure yielded a Debt-to-Equity (D/E) ratio of approximately 1.45. This is a crucial number. For a development-stage biotech, the industry average D/E ratio in 2025 is closer to 0.17 (or 17%), as most firms rely on equity raises and grants to fund risky R&D. LogicBio Therapeutics, Inc.'s ratio of 1.45 was significantly higher, indicating a greater reliance on debt relative to its shareholders' equity just prior to the acquisition, a sign of the financial pressure it faced.

The company's debt levels primarily consisted of a term loan from a Loan Agreement entered into in July 2019, which had a maturity date of June 1, 2024. The interest rate on this debt was the greater of the one-month U.S. LIBOR rate plus 6.25% or a floor of 8.75%. This is expensive debt for a company with no commercial revenue, and it points to the necessity of the eventual merger. The ultimate resolution of this debt was handled by Alexion as part of the acquisition, eliminating the near-term risk for the entity.

In 2025, the financing balance for LogicBio Therapeutics, Inc. has completely shifted from a precarious mix of debt and dilutive equity to a pure equity-funded model under its parent company. The need for debt issuances or refinancing activity is now managed at the AstraZeneca/Alexion level, removing the immediate 'going concern' risk that was present in its last public filing. The company's growth is now financed by the parent's internal capital, not external debt markets. If you want to dive deeper into the strategic goals that drove this acquisition, you can review the Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

The transition from a high D/E ratio to being debt-free under a parent entity is the ultimate de-risking move for an investor. It's defintely a case study in how a strategic acquisition can instantly resolve a challenging capital structure. The former debt-to-equity balance is now irrelevant; the current financing is 100% equity-backed by one of the world's largest pharmaceutical companies.

Here is a summary of the last reported capital structure versus the 2025 industry benchmark:

Next Step: Finance: Analyze the implied cost of capital reduction for LogicBio Therapeutics, Inc. by comparing the 8.75% debt interest rate to the parent company's internal cost of equity by end of next week.

Liquidity and Solvency

You're looking for a 2025 financial breakdown of LogicBio Therapeutics, Inc. (LOGC), but here's the critical context: the company was acquired by Alexion, AstraZeneca Rare Disease, with the deal closing in November 2022. So, there is no independent 2025 public financial data to analyze. To give you the most accurate picture of the company's final financial health as a standalone public entity, we must look at the last available filing-the Q3 2022 results, filed just before the acquisition.

Honestly, the company was in a tight spot, which is why the acquisition was an attractive exit. The liquidity position, while technically sufficient in the near-term, was rapidly deteriorating due to high cash burn from research and development (R&D) activities.

Assessing LogicBio Therapeutics, Inc.'s Liquidity

The company's final reported liquidity position, as of September 30, 2022, showed a decent buffer, but it was a biotech running on its cash reserves. The key metrics tell a clear story of a clinical-stage company with a finite runway.

The Current Ratio and Quick Ratio were nearly identical, which is typical for a biotech with no significant product inventory. A high ratio is usually great, but here it mainly reflects a large cash balance against a small base of current liabilities.

• Current Ratio: The ratio of 1.99 ($32.78 million / $16.43 million) meant the company had almost $2 in current assets for every $1 in current liabilities.
• Quick Ratio: At 1.99, this ratio was essentially the same, confirming the current assets consisted almost entirely of cash and near-cash items.

This high ratio gave them operational flexibility, but it's defintely not a sign of profitability-it's a measure of how much cash they had left to fund losses.

Working Capital and Cash Flow Trends

The working capital (Current Assets minus Current Liabilities) as of Q3 2022 was $16.34 million ($32.78 million minus $16.43 million). This positive working capital was a strength, but the trend in the cash flow statement showed it was shrinking fast.

Here's the quick math on the cash flow for the nine months ending September 30, 2022 (in thousands of USD):

The core issue was the $(17.48) million net loss for the nine-month period, driven by R&D expenses of $5.1 million and General and Administrative (G&A) expenses of $3.4 million in the third quarter alone. The business was in a capital-intensive phase, and the cash position had dropped from $53.48 million at the end of 2021 to $30.78 million by September 30, 2022.

The company itself noted in its Q3 2022 filing that there was 'substantial doubt' they would have enough funds to satisfy their obligations for the next twelve months without additional financing. This is the clearest sign of a liquidity concern. The acquisition by Alexion, AstraZeneca Rare Disease for $2.07 per share provided a necessary, and favorable, exit for shareholders facing a potential delisting and a severe capital crunch. Learn more about the company's initial goals here: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

The clear action for an investor in late 2022 would have been to accept the tender offer; the company's independent liquidity was unsustainable without a major, dilutive capital raise.

Valuation Analysis

You're looking for a clear-cut answer on whether LogicBio Therapeutics, Inc. (LOGC) is overvalued or undervalued in 2025, but the first and most critical insight is this: the public stock no longer exists. Any valuation metrics you see for LOGC in the 2025 fiscal year are based on speculation or a different company.

Alexion, AstraZeneca Rare Disease, a subsidiary of AstraZeneca, completed the acquisition of LogicBio Therapeutics, Inc. on November 16, 2022. This transaction was an all-cash tender offer that valued the company's common stock at $2.07 per share. The stock subsequently ceased trading on the NASDAQ Global Market, so any analysis of its public market valuation in 2025 is defintely moot.

Here's the quick math on the final, definitive valuation for public investors:

• Final Acquisition Price: $2.07 per share in cash.
• Transaction Date: November 16, 2022.
• Valuation Implication: This cash price represents the final, agreed-upon public market valuation, making traditional 2025 metrics irrelevant.

Why Traditional 2025 Ratios Are Not Applicable

For a company that has been a wholly owned subsidiary since late 2022, the standard valuation ratios for the 2025 fiscal year-like price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA)-are simply not calculable for public investors. LogicBio Therapeutics, Inc. is no longer required to file public financial statements as a standalone entity, so there are no public earnings, book value, or EBITDA figures to anchor a ratio.

To be fair, before the acquisition, like many clinical-stage biotech firms, LogicBio Therapeutics, Inc. had negative earnings, meaning its P/E ratio was also negative or not reported. For example, some data shows a last reported P/E ratio of -2.57 before the delisting, which is common for a company investing heavily in R&D with no product revenue. You simply can't value a biotech firm on P/E alone; it's a growth story, not an earnings one.

Stock Price Trends and Analyst Consensus

The stock price trend for LogicBio Therapeutics, Inc. over the 12 months leading up to November 2025 is a flat line at zero, because the stock is not trading. However, looking back at the 52 weeks before the acquisition announcement in October 2022, the stock price moved between a low of about $0.26 and a high of $3.53. The acquisition price of $2.07 per share was a significant premium to the trading price at the time of the announcement, which is a key signal of the value Alexion saw in the company's gene therapy technology.

As for analyst consensus, any current 'Buy,' 'Hold,' or 'Sell' rating you might find is either for a different company that shares the LOGC ticker or is a legacy rating that holds no weight. The ultimate consensus was the action of the buyer: a $68 million acquisition, which essentially translates to a definitive 'Buy' at $2.07 per share. If you want to understand the strategic value Alexion saw, you should read the Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC) to see how their genomic medicine platform fit into AstraZeneca's rare disease strategy.

Finally, LogicBio Therapeutics, Inc., as a clinical-stage biotech, did not pay a dividend, so dividend yield and payout ratios are 0% and not applicable. This is standard for companies reinvesting all capital into drug development.

Your next step is to focus your analysis on AstraZeneca's financial statements to understand the value contribution of the acquired LogicBio assets.

Risk Factors

You need to understand that investing in a company with the ticker LOGC today is fundamentally different than it was two years ago. The original LogicBio Therapeutics, Inc. (LOGC), a pioneering genomic medicine company, was acquired by Alexion, AstraZeneca Rare Disease, in November 2022. The risks for the biotech assets are now R&D and integration risks inside a massive pharmaceutical firm, but the ticker LOGC is now associated with a different entity, ContextLogic, Inc., which is pursuing a new acquisition-focused strategy. This is a crucial distinction.

Here's the quick math on the current public entity: ContextLogic, Inc. (LOGC) reported consolidated liquidity-cash, cash equivalents, and marketable securities-of approximately $218 million as of September 30, 2025. That's a strong cash position, but the risk lies in how they spend it.

Operational and Clinical Risks (The Biotech Assets)

The core internal risk for the original LogicBio Therapeutics, Inc. (LOGC) technology-the GeneRide and sAAVy platforms-is clinical execution and safety. Gene therapy is hard. The company's lead candidate, LB-001, for methylmalonic acidemia (MMA), previously faced a clinical hold from the FDA due to a serious adverse event, specifically thrombotic microangiopathy (TMA), in two patients during its Phase I/II SUNRISE trial. While the hold was lifted, this highlights the inherent, near-term operational risks:

• Safety Events: Gene therapy's complexity means unexpected side effects can halt a program instantly.
• Integration Failure: Alexion must effectively integrate the LogicBio team and technology; a failure to retain key R&D personnel or fully commit resources could de-value the acquisition.
• Platform Competition: The genomic medicine field is incredibly competitive. LogicBio's platforms must outperform rival gene editing (like CRISPR) and adeno-associated virus (AAV) delivery technologies to justify their continued, multi-million dollar investment.

The biggest risk here is that the technology, despite its promise, simply fails to clear the regulatory hurdles or is eclipsed by a competitor's superior platform.

Financial and Strategic Risks (The LOGC Ticker)

For investors tracking the LOGC ticker today, the risks are entirely strategic and financial, centered on the company's pivot to an acquisition vehicle. ContextLogic, Inc. is essentially a cash shell with a large net operating loss (NOL) carryforward, now seeking to acquire new businesses. This is a high-risk, high-reward strategy.

In the third quarter of 2025, the company reported a net loss of $1 million, with General and Administrative (G&A) expenses totaling $3 million, which included $1 million related to evaluating potential transactions. This shows a low burn rate, but the risks are clear:

What this estimate hides is the potential for a massive write-down if the first major acquisition fails. You are defintely betting on management's ability to pick a winner and integrate it seamlessly. You can learn more about the strategic vision that drives this decision here: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

Your next step: Monitor ContextLogic's SEC filings for the announcement of their first major acquisition-that will be the true test of this new business model.

Growth Opportunities

You need to know where the growth engine for LogicBio Therapeutics, Inc. (LOGC) stands right now, and the direct takeaway is that its future revenue potential is entirely tied to the pipeline acceleration within its parent company, Alexion, AstraZeneca Rare Disease. LogicBio was acquired in November 2022 for $2.07 per share in cash, a deal valued at approximately $68 million, which means it no longer trades independently and has no standalone public 2025 financial data.

The real opportunity for investors is understanding how LogicBio's core technology platforms-GeneRide and sAAVy-will drive growth for AstraZeneca's genomic medicine strategy. This wasn't a product acquisition; it was a platform acquisition. Its value is in the science, not a sales forecast.

Platform Innovation as the Core Growth Driver

The company's primary growth drivers are its proprietary technology platforms, which are now being integrated into Alexion's substantial R&D budget. The GeneRide platform is a game-changer because it enables precise gene insertion by harnessing the cell's natural deoxyribonucleic acid (DNA) repair process. This approach is designed to lead to more durable therapeutic protein expression levels, which is a huge competitive advantage in the gene editing space.

The sAAVy platform, an adeno-associated virus (AAV) capsid engineering technology, is focused on optimizing gene delivery, aiming for better potency and tissue targeting. Plus, their proprietary manufacturing process, mAAVRx, is designed to improve viral vector yields and product quality, addressing a major bottleneck in the gene therapy industry.

• GeneRide: Uses natural DNA repair for durable gene insertion.
• sAAVy: Optimizes AAV capsids for better gene delivery.
• mAAVRx: Aims to improve viral vector manufacturing yields.

Pipeline Progress and Future Revenue Potential

The near-term revenue potential for LogicBio's former assets is centered on the progress of its lead clinical candidate, LB-001, which is in Phase I/II clinical trials for the treatment of methylmalonic acidemia (MMA). This is a rare, life-threatening genetic disorder, and a successful therapy would defintely be a blockbuster for Alexion. The FDA had placed a clinical hold on the trial in early 2022 due to drug-related serious adverse events (thrombotic microangiopathy, or TMA), but the hold was lifted in May 2022 after protocol amendments were made to include enhanced monitoring.

LB-001 is currently in Phase II clinical development under Alexion Pharmaceuticals, according to data from December 2024. This is a crucial milestone, as advancing a Phase II asset is where the value really starts to compound. Other preclinical products, like the investigational therapy LB-301 for Crigler-Najjar syndrome, are also now part of Alexion's broader pipeline, representing future revenue streams.

Competitive Strengths and Market Position

LogicBio's competitive advantage lies in its GeneRide platform's ability to achieve non-viral gene insertion without the need for nucleases (molecular scissors), which can cause off-target effects. This is a cleaner, potentially safer approach to in vivo (in the body) gene editing compared to some competitors. Alexion's acquisition was a clear move to bolster its genomic medicine strategy, betting $68 million that this technology will give them a long-term edge in the rare disease market. For Alexion, LogicBio's platforms are an immediate way to accelerate their R&D efforts and expand their focus beyond their existing complement-system drugs.

Here's the quick math on the pre-acquisition valuation: the $2.07 per share acquisition price represented a massive premium of around 660% over the stock's closing price just before the deal was announced. That premium tells you the market-and Alexion-saw immense value in the underlying technology and the experienced rare disease R&D team, which they retained. If you want to dive deeper into the players who were tracking this value, you should check out Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who's Buying and Why?